CN103764157A - 流感病毒感染抑制剂 - Google Patents
流感病毒感染抑制剂 Download PDFInfo
- Publication number
- CN103764157A CN103764157A CN201180073004.7A CN201180073004A CN103764157A CN 103764157 A CN103764157 A CN 103764157A CN 201180073004 A CN201180073004 A CN 201180073004A CN 103764157 A CN103764157 A CN 103764157A
- Authority
- CN
- China
- Prior art keywords
- extract
- influenza virus
- flos papaveris
- papaveris rhoeadis
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 17
- 230000009385 viral infection Effects 0.000 title description 6
- 239000003112 inhibitor Substances 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 26
- 206010022000 influenza Diseases 0.000 claims abstract description 26
- 241000700605 Viruses Species 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 241000628997 Flos Species 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 240000001090 Papaver somniferum Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 102000045576 Lactoperoxidases Human genes 0.000 description 3
- 229940057428 lactoperoxidase Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005723 virus inoculator Substances 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 108010023244 Lactoperoxidase Proteins 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 101001099470 Bos taurus Lactoperoxidase Proteins 0.000 description 1
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000004674 Papaver rhoeas Species 0.000 description 1
- 235000007846 Papaver rhoeas Nutrition 0.000 description 1
- 240000000103 Potentilla erecta Species 0.000 description 1
- 235000016551 Potentilla erecta Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 235000016975 Ribes fasciculatum Nutrition 0.000 description 1
- 241000735589 Ribes fasciculatum Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 239000008805 kakkon-to Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/36—Vegetable material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
提供一种有抑制流感病毒感染效果的组合物。将虞美人用水提取，对该提取液通过冷冻干燥进行纯化，以将所得的提取物作为有效成分为特征的抗流感病毒剂。
Description
技术领域
提供一种有抑制流感病毒感染效果的组合物。
背景技术
如果感染流感病毒，会出现高烧、头痛、关节痛、全身无力等临床症状，也有发生死亡的情况。流感病毒感染力强，与一般的感冒不同，有在短期内引发爆发式的流行的特征。
作为流感的预防、治疗方法，通常认为可通过接种疫苗预防或通过神经氨酸酶抑制剂等药物治疗。但是，由于疫苗根据流感病毒的类型其效果有显著差异而并非通用，药物也有副作用和出现耐药性病毒的问题。
在此背景下，开发了预防、治疗流感病毒感染的组合物，公开了以下显示出对流感病毒感染有抑制效果的成分：葛根汤（非专利文献1）、乳铁蛋白和乳过氧化物酶（非专利文献2）、孢子型乳酸菌（专利文献1）、色甘酸钠（专利文献2）、来源于哺乳动物初乳的蛋白质组分（专利文献3）、含有唾液酸糖链的聚合物（专利文献4）、荞麦（专利文献5）、黑茶藨子（专利文献6）、各种植物提取物（专利文献7、8）等。然而这些成分尚不能说显示了足够的流感病毒感染抑制效果，需要进一步开发预防和治疗方法。
本发明人以提供显示出有流感病毒感染抑制效果的物质为目的探究的结果是，发现虞美人提取物显示出有效的流感病毒感染抑制效果。本发明认为有流感病毒感染抑制效果的虞美人（学名：Papaver rhoeas L.）是罂粟科植物，别名虞美人草，认为有镇静、催眠、止痛作用等，被用作镇咳药和镇静剂，但完全不知道其病毒的感染抑制效果。
关于虞美人的药理作用，与含有草药的免疫赋活剂有关的专利（专利文献9）中，草药的例子仅记载了虞美人，但是文献缺乏发明的具体性，也没有暗示虞美人的病毒感染抑制效果。
现有技术文献
专利文献
专利文献1：日本专利申请特开2008-13543号公报
专利文献2：日本专利申请特开2004-352712号公报
专利文献3：日本专利申请特开2009-190994号公报
专利文献4：日本专利申请特开2008-31156号公报
专利文献5：专利第4185996号说明书
专利文献6：日本专利申请特开2009-269861号公报
专利文献7：日本专利申请特开2005-343836号公报
专利文献8：日本专利申请特开2004-59463号公报
专利文献9：日本专利申请特开2002-370993号公报
非专利文献
非专利文献1：Kurokawa M.等、Antiviral Research、2002年、56卷、183-188页、中药葛根汤在小鼠流感病毒感染早期阶段对白细胞介素-12水平增加的作用（Effect of interleukin-12level augmented by Kakkon-to,aherbal medicine,on the early stage of influenza infection in mice）.
非专利文献2：Shin K.等、Journal of Medical Microbiology、2005年、54卷、717-723页、口服乳铁蛋白和乳过氧化物酶对小鼠流感病毒感染的影响（Effects of orally administered bovine lactoferrin andlactoperoxidase on influenza virus infection in mice）.
发明内容
发明所要解决的技术问题
本发明提供一种有抑制流感病毒感染效果的组合物。
解决技术问题所采用的技术方案
本发明涉及以将虞美人提取物作为有效成分为特征的抗流感病毒剂。
本发明还涉及以将虞美人用水提取，对该提取液通过冷冻干燥进行纯化，将所得的提取物作为有效成分为特征的抗流感病毒剂。
另外，本发明涉及含虞美人提取物的具有抗流感病毒作用的饮食品。
发明的效果
本发明的虞美人提取物具有促进IgA分泌效果和流感病毒感染抑制效果，认为能造成不易感染流感的体质，是可能的能强化润喉糖功能的新材料。
附图说明
图1：显示接种流感病毒16天为止，虞美人提取物给药组和对照组的小鼠生存率的图。
具体实施方式
本发明人对显示了流感病毒感染抑制效果的物质进行探索的结果是着眼于虞美人提取物，让给予该虞美人提取物进行饲养的小鼠和未给予的小鼠感染同等量的流感病毒，观察之后的情况发现，给予虞美人提取物的小鼠因感染流感病毒造成的体重减轻较为缓和，其存活率也有改善的倾向。
以下以具体例作为实施例进行说明。还有，本发明并不局限于以下的具体例。
[实施例]
(实施例1)
虞美人热水提取物的制备
粉碎100g虞美人（花）后，加入相对于试样重量的10倍量的水，在70℃下提取2小时。过滤不溶物后，冷冻干燥所得到的提取液，得到虞美人热水提取物37.5g。
(实施例2)
通过向小鼠反复舌下给药得到的流感病毒感染抑制效果
将30只7周龄的小鼠(BALB/c系)分为对照组（14只）和给药组（16只），用普通饲料（MF，东方酵母公司）饲养。给药组从饲养开始时以4mg/天的用量每天舌下给予虞美人（花）热水提取物的水溶液，对照组仅舌下给予同量的水。在第四周时麻醉下鼻腔接种流感病毒（100pfu/50μl PBS/只），测量体重直至接种后16天为止。使用流感病毒株A/PR/8/34（H1N1），并在感染病毒后仍然舌下给予虞美人（花）热水提取物。病毒接种时各试验动物的体重如以下表1所示，两组间无显著差异。
[表1]
表1接种病毒时各动物的体重
本实施例中得到的结果如表2、表3及图1所示。
表2及表3显示了接种流感病毒后16天为止的小鼠体重克数变化，并表示了虞美人提取物给药组和对照组的个别数据及平均数据。
图1是对接种流感病毒16天为止虞美人提取物给药组和对照组的小鼠存活率进行绘图而得的。
表2及表3中，天数是接种流感病毒后的经过天数，体重变化表示从接种病毒时的体重开始的变化量。表2及表3中的×表示小鼠死亡。
如图1所明确显示的，在接种流感病毒后经过16天，相对于对照组中14只存活5只（存活率36％），虞美人提取物给药组中16只存活10只（存活率63％）。对数秩检验的结果是，第12天为止的存活率给药组相对于对照组显著较高，第16天为止的存活率给药组相对于对照组有高的趋势。
另外，关于体重变化，t-检验的结果是，从第3天到第7天为止的期间与对照组相比，给药组的体重减轻被明显地抑制了，认为给药组因感染病毒造成的体重减轻较为缓和。
由以上结果，认为通过给予虞美人提取物可抑制因病毒感染造成的小鼠死亡和体重减轻。
[表2]
[表3]
接着，使用显示了流感病毒感染抑制效果的本发明的虞美人提取物依常法配制成药丸、口香糖、糖果、巧克力、饼干、软糖、压片糖、冰淇淋、雪糕、饮料。以下显示它们的配方。
(实施例3)
按照以下配方配制药丸。
(实施例4)
按照以下配方配制口香糖。
(实施例5)
按照以下配方配制糖果。
(实施例6)
按照以下配方配制巧克力。
(实施例7)
按照以下配方配制饼干。
(实施例8)
按照以下配方配制软糖。
(实施例9)
按照以下配方配制压片糖。
(实施例10)
按照以下配方配制片剂。
(实施例11)
按照以下配方配制冰淇淋。
(实施例12)
按照以下配方配制雪糕。
(实施例13)
按照以下配方配制饮料。
产业上利用的可能性
本发明的虞美人提取物由于显示出流感病毒感染抑制效果，可适用于用于抑制流感病毒的各种药品及饮食品。
Claims (3)
1.抗流感病毒剂，其特征在于，以虞美人提取物为有效成分。
2.抗流感病毒剂，其特征在于，将虞美人用水提取，对该提取液通过冷冻干燥进行纯化，将所得的提取物作为有效成分。
3.饮食品，其特征在于，含虞美人提取物，具有抗流感病毒作用。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2011/004701 WO2013027245A1 (ja) | 2011-08-24 | 2011-08-24 | インフルエンザウイルス感染抑制剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103764157A true CN103764157A (zh) | 2014-04-30 |
Family
ID=47746027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180073004.7A Pending CN103764157A (zh) | 2011-08-24 | 2011-08-24 | 流感病毒感染抑制剂 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2749287A4 (zh) |
| KR (1) | KR101765995B1 (zh) |
| CN (1) | CN103764157A (zh) |
| BR (1) | BR112014004159A2 (zh) |
| WO (1) | WO2013027245A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021194436A1 (en) * | 2020-03-26 | 2021-09-30 | Nanobiomed Sağlik Ve Yaşam Bilimleri A. Ş. | The natural antiviral and anti-inflammatory compound consist of bioflavonoids which extracted from papaver rhoeas red petals |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002370993A (ja) | 2001-06-13 | 2002-12-24 | Bussan Biotech Kk | ハーブを含む免疫賦活剤 |
| JP4185996B2 (ja) | 2002-04-02 | 2008-11-26 | 島根県 | 抗インフルエンザウイルス剤 |
| JP4216013B2 (ja) | 2002-07-26 | 2009-01-28 | 株式会社ロッテ | 抗インフルエンザウイルス剤 |
| ITRM20030154A1 (it) | 2003-04-03 | 2004-10-04 | D M G Italia S R L | Sciroppo antireflusso. |
| JP2004352712A (ja) | 2003-05-08 | 2004-12-16 | Fujisawa Pharmaceut Co Ltd | インフルエンザの予防または治療剤 |
| JP4669670B2 (ja) | 2004-06-04 | 2011-04-13 | 株式会社ロッテ | 抗インフルエンザウイルス剤及びこれを吸着、含浸、添加させてなるインフルエンザ感染抑制用品 |
| JP5232404B2 (ja) | 2006-06-07 | 2013-07-10 | 第一三共ヘルスケア株式会社 | 有胞子性乳酸菌含有抗感冒ウイルス又は抗インフルエンザウイルス用組成物 |
| JP2008024695A (ja) | 2006-06-19 | 2008-02-07 | Morishita Jintan Kk | シームレスカプセル |
| JP2008031156A (ja) | 2006-07-07 | 2008-02-14 | National Univ Corp Shizuoka Univ | 抗ウイルス剤 |
| JP2009190994A (ja) | 2008-02-13 | 2009-08-27 | Kitasato Institute | 抗インフルエンザウイルス剤、及びその有効成分の製造方法 |
| JP2009269861A (ja) | 2008-05-08 | 2009-11-19 | Tama Seikagaku Kk | カシス果実由来のウィルス感染予防・治療剤 |
| KR101896123B1 (ko) * | 2010-03-04 | 2018-09-07 | 가부시키가이샤 롯데 | 이뮤노 글로불린 a 분비 촉진제 |
-
2011
- 2011-08-24 KR KR1020147007135A patent/KR101765995B1/ko active IP Right Grant
- 2011-08-24 WO PCT/JP2011/004701 patent/WO2013027245A1/ja unknown
- 2011-08-24 CN CN201180073004.7A patent/CN103764157A/zh active Pending
- 2011-08-24 BR BR112014004159A patent/BR112014004159A2/pt not_active IP Right Cessation
- 2011-08-24 EP EP11871336.1A patent/EP2749287A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2749287A4 (en) | 2015-05-13 |
| WO2013027245A1 (ja) | 2013-02-28 |
| BR112014004159A2 (pt) | 2017-03-01 |
| KR101765995B1 (ko) | 2017-08-07 |
| EP2749287A1 (en) | 2014-07-02 |
| KR20140068074A (ko) | 2014-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7638146B2 (en) | Anti-AIDS drug | |
| CN114502184A (zh) | 防治冠状病毒感染的包括杜英萃取物的药物和食品组合物 | |
| ES2442265T3 (es) | Composición vírica anti-influenza que contiene extracto de corteza o tallo de Alnus japonica | |
| EP3053596B1 (en) | Mucosal vaccine composition | |
| CN102846736A (zh) | 一种治疗羊痘的中药制剂 | |
| CN103764157A (zh) | 流感病毒感染抑制剂 | |
| CN105395614A (zh) | 一种荷叶生物碱提取方法及其应用 | |
| CN105530958A (zh) | 粘膜疫苗组合物 | |
| CN104189291A (zh) | 一种治疗上呼吸道感染的中药组合物 | |
| WO2017170962A1 (ja) | 抗ウイルス剤及び抗ウイルス用食品 | |
| WO2004112802A1 (en) | Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 inhibiting the swine influenza (siv) and transmissible gastroenteritis coronavirus (tgev) | |
| KR102551027B1 (ko) | 장수진흙버섯 추출물을 포함하는 항바이러스용 조성물 | |
| CN101947290A (zh) | 一种具有滋阴作用的药物 | |
| JP5372547B2 (ja) | 免疫グロブリンａ産生促進剤 | |
| CN106138259B (zh) | 一种治疗风热感冒的中药组合物及其制备方法 | |
| JP2015110680A (ja) | 抗ウイルス剤 | |
| JP5945317B2 (ja) | インフルエンザウイルス感染抑制剤 | |
| WO2018226447A1 (en) | Method for inhibiting inflammation caused by gram-negative bacteria infection | |
| CN102781457A (zh) | 免疫球蛋白a分泌促进剂 | |
| CN103501798A (zh) | 抗新型流感病毒剂 | |
| TW201818951A (zh) | 南洋山蘇水萃物的用途 | |
| CN101204581B (zh) | 实时个性化艾滋病毒禽蛋抗体制剂及其制备方法与应用 | |
| CN103585462B (zh) | 一种抗球虫中药合剂及其制备方法 | |
| WO2019032951A1 (en) | METHOD OF TREATING INFECTION WITH DENGUE VIRUS | |
| CN105664080A (zh) | 一种治疗流行性感冒的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1195005 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140430 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1195005 Country of ref document: HK |